Production (Stage)
Castle Biosciences, Inc.
CSTL
$16.10
$0.211.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -369.53% | 322.65% | -74.56% | 452.01% | 1.78% |
| Total Depreciation and Amortization | 416.02% | 62.89% | 5.76% | 0.24% | 3.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.48% | -58.07% | 70.63% | -11.99% | 8.54% |
| Change in Net Operating Assets | -1,127.79% | 155.54% | -59.41% | 110.17% | -345.19% |
| Cash from Operations | -124.77% | 4.40% | -2.75% | 451.10% | -136.77% |
| Capital Expenditure | 37.36% | -18.64% | -21.97% | 42.86% | -141.29% |
| Sale of Property, Plant, and Equipment | 28.57% | 75.00% | 100.00% | -60.00% | 66.67% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -232.78% | 258.41% | 48.02% | -53.40% | -171.87% |
| Cash from Investing | -488.75% | 139.02% | 30.95% | -8.71% | -156.79% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 0.00% | -8.33% | -118.18% | 69.44% | 0.00% |
| Issuance of Common Stock | -3.14% | -52.69% | 222.75% | -42.11% | 53.05% |
| Repurchase of Common Stock | 60.57% | -392.97% | -110.41% | -29.75% | 88.19% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 71.16% | -742.60% | 1,895.24% | -99.61% | 422.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -221.29% | 163.66% | 257.87% | 116.51% | -308.61% |